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Mathematical Modeling of HIV Dynamics
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A Review
Pablo S. Rivadeneira,1,2 Claude H. Moog,2 Guy-Bart Stan,3 Cecile Brunet,4,5 Franc¸ois Raffi,4,5
Virginie Ferre´,4,5 Vicente Costanza,1 Marie J. Mhawej,2 Federico Biafore,6 Djomangan A. Ouattara,2
Damien Ernst,7 Raphael Fonteneau,7 and Xiaohua Xia8
Abstract
This review shows the potential ground-breaking impact that mathematical tools may have in the analysis and the
understanding of the HIV dynamics. In the first part, early diagnosis of immunological failure is inferred from the
estimation of certain parameters of a mathematical model of the HIV infection dynamics. This method is supported
by clinical research results from an original clinical trial: data just after 1 month following therapy initiation are
used to carry out the model identification. The diagnosis is shown to be consistent with results from monitoring
of the patients after 6 months. In the second part of this review, prospective research results are given for the design
of individual anti-HIV treatments optimizing the recovery of the immune system and minimizing side effects. In
this respect, two methods are discussed. The first one combines HIV population dynamics with pharmacokinetics
and pharmacodynamics models to generate drug treatments using impulsive control systems. The second one is
based on optimal control theory and uses a recently published differential equation to model the side effects pro-
duced by highly active antiretroviral therapy therapies. The main advantage of these revisited methods is that the
drug treatment is computed directly in amounts of drugs, which is easier to interpret by physicians and patients.
Key words: aid for diagnosis; AIDS; apoptosis; dynamical systems; HIV; modeling; nonlinear control; pharma-
codynamics; pharmacokinetics
Introduction
Mathematical modeling has made a substantial im-pact on our thinking and understanding of HIV-1 in-
fection. A large number of deterministic models have been
developed to describe the immune system and its interaction
with HIV as well as the effects of drug therapy. The extended
cooperation between A. Perelson and D. Ho using clinical
data and mathematical modeling has been used to elucidate
the principles that govern HIV and immune system dynamics
in relation to antiviral drug therapy.1–3
Other studies revealed the lifetime of infected cells, which
actively produce copies of the virus, and the high replication
rate of HIV in the body. These results reinforce the idea that
HIV is a dynamic disease encompassing a number of differ-
ent time scales, running from hours to months.
In this review, the HIV dynamics are analyzed from the
point of view of control systems. Clinical research results
show that parameter identification methods constitute an ef-
ficient means to characterize critical patients, just 1 month
after initiation of a new therapy.4–7 Thus, parameter identifi-
cation methods provide information to physicians that
can be very useful for the diagnosis of patients under clinical
failure.8 Prospective research of control methods recently
published (without clinical data) is discussed as well and re-
search directions are given for the design of an optimal,
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nonconstant drug dosage therapy to control the virus dynam-
ics and to minimize undesired side effects.9–11
Following this line of interdisciplinary research, the achieve-
ments that this review article emphasizes are as follows:
1. A clinical trial has been set up for the first time to show
that mathematical systems analysis is useful to help cli-
nicians in an early diagnosis and in taking decisions for
treating HIV-infected patients,
2. An optimal (time-varying) dosage is generated by
taking into account the desired dynamics for the im-
mune system as well as the side effects generated by
antiretroviral drugs after initiation of the treatment.
This is one of the perspectives offered by a mathemat-
ical approach.
3. The control action (therapy) is computed in terms
of the drug dosage in milligrams, which is significant
for real-life practitioners, whereas earlier articles
consider the efficiency of drugs as the control input.
Pharmacokinetic and pharmacodynamic models are
included in the HIV model.
The outline of this review is as follows. The next section
introduces a model of the infection dynamics. The clinical
research results are then described, including the methods,
and a discussion of the results. Namely, the identified
model is argued to be an efficient tool for characterizing crit-
ical patients and for the diagnosis of clinical failure within 1
month after initiation of a new therapy. More prospective
research is reviewed, and strategies for the control of the in-
fection dynamics using drug treatments are revisited in the
framework of engineering and computational methods. For
these prospective strategies, only in silico results are pre-
sented because no clinical study is available yet. Finally,
conclusions are presented.
Basic Modeling of the Infection Dynamics
Several nonlinear models have been developed to describe
the dynamics of the HIV-1 virus, which take into account
the kinetics of the HIV infection with different cell popula-
tions; for example, macrophages, cytotoxic T lymphocytes,
latently infected CD4 + T cells as well as the lymphoid com-
partments.12,13
With a goal of providing useful diagnostic information
and controlling the infection, the main characteristics
of the HIV dynamics can be modeled based on a relatively
simple set of ordinary differential equations. In fact, the
simplest model of the HIV/AIDS dynamics (which is used
herein) can be understood through the interactions of
healthy CD4 + cells (T), infected CD4 + cells (T*), and
free viruses (V)3:
_T = s dT  (1g1)bTV ATT (1)
_T = (1g1)bTV  lT (2)
_V = (1g2)kT  cV (3)
where healthy CD4 + cells (T) are produced from the thymus
at a constant rate s and die with a half-life time equal to 1d The
healthy cells are infected by the virus at a rate that is propor-
tional to the product of their population size and the amount
of free virus particles. The proportionality constant b is an
indication of the effectiveness of the infection process.
The term ATT* is included to take into account that, in the
presence of infected cells (T*), healthy CD4 + cells undergo
activation-induced apoptosis.7,14
The infected CD4 + cells result from the infection of
healthy CD4 cells and die at a rate l. Free virus particles
are produced from infected CD4 cells at a rate k and die
with a half-life time equal to 1
c
. The parameters g1 and g2 rep-
resent the efficacy of an anti-HIV treatment, which is gener-
ally a cocktail of drugs composed of reverse transcriptase
inhibitors and protease inhibitors. Reverse transcriptase in-
hibitors are usually considered to affect the parameter b
and protease inhibitors, the parameter k.3,15,16 In particular,
g1 = g2 = 0 represents a null therapy, while g1 = g2 = 1 denotes
a 100% effective therapy. Equation 3 takes into account
the fact that one virus particle can only infect one single
CD4 + cell.
Clinical Research: EDV05 Clinical Trial Design
and Early Diagnosis of Therapeutic Failure
Among a general population of HIV-infected patients
starting a new therapy, some individuals will eventually un-
dergo a so-called immunological failure. One main contribu-
tion reviewed here is to show that parameter identification is
able to predict such failures after 1 month from the beginning
of the treatment, while the immunological failure usually
takes 6 months to be diagnosed during a standard clinical
monitoring.
As previously stated, immunological failure is clinically
declared when the amount of CD4 T cells remains under
200 CD4/mm3 during 6 months of efficient treatment.5,17,18
A treatment is defined as efficient, if it yields a decrease of
the viral load below the detectable threshold of 50 copies/
mL and keeps the viral load below this limit afterwards.
A central paradox for HIV patients who are in immunolog-
ical failure is that their viral load seems too low to be able to
deplete the CD4 + population by direct killing alone. In this
respect, the first studies8 relate immunological failure to a
dysfunctional thymus, which is unable to produce a sufficient
amount of healthy CD4 + T cells. However, a different point
of view is argued in the section Prospective Research: Infec-
tion Control and Drug Dosage, which relates immunological
failure to an important activation-induced apoptosis phenom-
enon in the transient stage of the infection. This point of view
is supported by several research articles,7,14,19–24 based on
thymic function having little chance to vary within a healthy
adult population. Whether immunological failure is predom-
inantly due to a badly damaged thymus or to an important
activation-induced apoptosis phenomenon remains an open
question.
Methods
To generate useful data for the characterization of the im-
munological failures, the EDV05 trial was initiated at the
University Hospital of Nantes in February 2005, and six pa-
tients were included in the first part of this trial. In 2007 and
2008, 10 other patients were enrolled. The main conditions
for each patient (female or male) to be included in the trial
were as follows: aged over 18 years old, having been infected
by the HIV-1 or HIV-2 type virus, having no co-infection
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with hepatitis B or hepatitis C virus during the 6 months pre-
ceding their inclusion in the trial, starting an antiretroviral
treatment at the beginning of the trial, and not showing any
resistance to the treatment that will be administrated.
The measured data consisted of the viral load and the to-
tal CD4 T cells. Eleven samples were collected during 3
months, but the relevant information about the dynamics
(six or seven blood samples) was taken within the first 20
days. This specific sampling protocol enables a first estima-
tion of all the parameters of the mathematical model (Equa-
tions 1–3 with g1 = 0).4,8 From day 30 to day 90, only four or
five other samples were taken, with a sampling time of about
15 days. Since the measured viral load values depend on the
laboratory protocol used to quantify the RNA copies,16,25–28
it was decided for each patient to perform all the measure-
ments of the viral load at the same time with the same proto-
col. Thus, the 11 blood samples from each patient were kept
frozen (at 80C) until the end of the trial (see Fig. 1). The
measurements were done at the same time using the Roche
Taqman 48TM test, with a detectable threshold of 50 cop-
ies/mL (CD4 T cells and virus load values for the 16 patients
are given in table 2 of Prud’homme et al.29).
Based on clinical observations, Mhawej et al.4 concluded
that the identification of the parameters of the dynamical
model (Equations 1–3 with g1= 0) allows defining a quantifi-
able immunological status. Since available measurements typ-
ically contain the total (uninfected and infected) CD4 T cells
and free virions, the parameters of the proposed model can
only be determined from these output measurements (blood
samples) under certain identifiability conditions.30
The identification method used in this reviewed study was
developed by Ouattara5 and Ouattara et al.8 and implemented
in software available in reference 6. The method is based on
the Monte Carlo approach, combined with a simplex opti-
mization method. To avoid local optima, random initial
conditions were drawn from uniform distributions in the ad-
missible parameter space and corresponding estimates were
computed. Using the median and interquartile range of the
estimates’ distributions, reliable estimations and confidence
intervals of the parameters were deduced. For Equations 1–
3 (with g1 = 0), a number of 1000 randomizations was suffi-
cient to obtain stable and robust results.8 The calibration of
the algorithm was as follows:
 Life-time parameters were set to constant values, which
relied on typical values published in Ouattara et al.8
These were d= 0.01/d, l = 0.05/d, and c = 0.3/d.
 According to the biological characteristics of the infec-
tion, the other parameters were constrained to be bounded
in the following intervals: s 2 [1E 5, 20], b2 [1E
20, 1],A2 [1E 20, 1], k 2 [1E 20, 1Eþ 8].
 The uniform distributionsU used for the initial conditions
were: UA 2 [1E 10, 0:5],Ub 2 [1E 10, 1E 5],
Us 2 [1E 5, 10],Uk 2 [1, 5Eþ 3]:
Parameters in the mathematical model of the HIV/AIDS
infection are related to the immunological status of the pa-
tient. For instance, s is the natural production rate of CD4
T cells by the thymus. So, a low value for s is representative
of a badly damaged immune system. Similarly, a large value
for A indicates an important activation-induced apoptosis
phenomenon.
When the apoptosis phenomenon is not considered, an aux-
iliary mathematical characterization of the immunological
failure can be stated using the identified parameters as follows.
The immune potential is given by the maximal level of
CD4 + T cells that can be reached if a 100% efficient treat-
ment is administered. This maximal level is obtained by set-
ting V = 0 in Equation 1 and computing its equilibrium point
as Dmax = sd : So, patients with a normal function of the thy-
mus must have a Dmax > 200 CD4/mm3.
But in practice, it is desirable to reach the equilibrium
Dmax within a reasonable time (around 6 months in general).
Thus, a more restrictive evaluation of the status of the im-
mune system is provided by the time t200 required to reach
the critical threshold of 200 CD4/mm3. For patients who
are not in immunological failure, t200 is less than 6 months.
More generally, tD denotes the time required to reach the
level D of CD4 T cells count in the case of a 100% efficacy
of the therapy. tD is computed as follows
17:
tD = max
1
d
 loge 1
d
s
D
 
þ loge 1
d
s
T(0)
  
, 0
 
(4)
Summarizing, patients are declared to be critical if they
belong to one of the following groups:
 A low value of the parameter s (s£ 3) and a high value
of the parameter A (A >102)
 Dmax > 200 CD4/mm3
 Dmax > 200 CD4/mm3, but t200 > 6 months
Results
To characterize critical patients, two identifications of the
parameters were done using the data collected in the first
month of the trial; that is, the first seven or eight samples
were used. The first identification only considered a de-
graded functionality of the thymus; that is, the parameter
A was taken equal to zero. The second identification took
into account the activation-induced apoptosis phenomenon
but a normal thymic function (s = 6mm3/d). The numerical
results of the identification of the parameters sjA = 0 and
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FIG. 1. Viral load time evolution for four patients. The
samples are taken frequently at the beginning of the trial.
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Ajs = 6 for each patient in the EDV05 trial and the analysis of
the remaining parameters of the dynamical model can be
found in previous articles.4,8,29
Discussion
In Rivadeneira et al.,29 the last column of table 1 displays
the theoretical time t200 necessary to recover a CD4 level
above 200 CD4/mm3. This theoretical time t200 was computed
from Equation 4 using the parameter identification method
based only on the samples from the first 3 weeks after initiation
of the therapy. According to this theoretical time t200, five pa-
tients are predicted to be in immunological failure since they
will not recover the desired CD4 level of 200 CD4/mm3 within
6 months. The remaining 11 patients are predicted to recover
within 6 months, and among those, 10 patients are even pre-
dicted to recover the desired CD4 level within 3 months.
Based on the identification of parameters s or A only, six
patients are declared to be critical: they are exactly those
for whom t200 > 3 months. Patients 3, 7, 11, 13, 15, and 16
were critical patients because they had the highest values
of apoptosis parameter A and concurrently the lowest values
of the parameter s. The immunological failure of patient 3
was clinically confirmed after 3 months of monitoring.
Patient 11 was 59 years old at the time of the trial and was
the oldest among the 16 patients who were included. In
this special case, the small value of s or the high value of
A rather indicated poor dynamics of the immune system,
which is standard at the age of 60. Similar observations
were made for patient 13 who was 49 years old at the begin-
ning of the trial. The clinical monitoring of patient 15 shows
co-existing tuberculosis that weakened the immunological
system and explained the estimated values of s and A. Patient
16 was only 18 years old when he was enrolled in the trial.
He had a very low level of 3 CD4/mm3. This patient was
very young and his immunological system proved after
6 months its ability to recover from its critical status.8,29 t200
lay within the range 3 months< t200< 6 months (predicted
from Equation 4 and can be found in table 1 in reference 29).
The last column of the table 2 in Rivadeneira et al.29 dis-
plays the immunological status of the patients after 6 months.
The latter was fully consistent with the previous results. The
11 patients reaching the level 200 CD4/mm3 within 6 months
were all correctly identified, which suggests a good sensitiv-
ity of the measure based on the identified parameters s and
A. The five patients having a level below 200 CD4/mm3
after 6 months were correctly identified as well, which again
suggests a good specificity of the measure. These latter state-
ments deserve an exhaustive statistical study, which is be-
yond the scope of this review article.
The conclusion of these results is that the identification of
the parameters in Equations 1–3 can be used for the early di-
agnosis of immunological failure just after the first month
following initiation of a new therapy. The peculiarities of
each patient such as therapy adherence, age, or other circum-
stances must be taken into account by the physician to make
a final clinical decision.
Prospective Research: Infection Control
and Drug Dosage
In the previous section, the parameters of a model were
identified for patients under treatment. In this section, a
model for a patient without therapy will be considered and
used to review two special drug-scheduling therapies
designed using control engineering methods.
HIV drug-scheduling strategies have drawn attention
from the biomedical and control engineering communities
and many control strategies have been proposed for thera-
peutic treatment. For instance, state feedback and optimal
control of HIV infection have been explored in several
works.9,15,31–36 However, most of these methods consider
the efficacy of the drugs as the control variable, which results
in strategies that are quite hard to use in practice since drug
efficacy is typically not expressed in terms of administered
drug amounts. To circumvent this drawback, pharmacoki-
netic and pharmacodynamic considerations can be included
in the model to relate efficiency with drug dosage,10 as it is
shown next. Therapeutic treatments, designed using control
theory, are theoretical results with potential important im-
pact. The parameters used in the following models were
extracted from data available in the HIV literature and corre-
spond to an average patient not following any therapy.
Antiretroviral therapy slows the clinical progression of
HIV infection at the beginning of the therapy. However
drug resistance due to viral mutation typically occurs after
some time and poses a challenging problem for long-term
treatments. Some studies have speculated that alternating
between drug regimens on a fixed schedule might forestall
therapeutic failure. Early stages of the virus evolution are as-
sumed to be mutation free. During further stages, the virus
mutation can no longer be ignored. This is considered for in-
stance in Hernandez-Vargas et al.,37 in which the mutation
of the virus is modeled using switching systems, which in-
clude 64 virus strains and three drug combinations. This
issue remains the topic of ongoing research.
In the results included in this review, the mathematical
models do not take into account drug resistance and mutation
of the virus. The drug therapies generated based on these
models were designed to act at the first stages of the thera-
peutic regimen, during which the probability that the virus
develops some mutation is still low. Two control policies
are considered: feedback linearization and optimal control.
Feedback linearization control applied to HIV
drug scheduling
The problem of drug administration is classically divided
into two phases: a so-called pharmacodynamic phase that re-
lates the concentration of drugs at the site of action to the
magnitude of the effect produced, modeled as g = w(t)
w(t)þw50,
and a pharmacokinetic phase that relates dose, frequency,
and route of administration to drug level–time relation-
ships in the body, mathematically described as _w =Kwþ
u(t)d(t sk). The parameter w50 is the concentration of
drug that lowers the viral load by 50%, K is the elimination
rate constant of the drug, u(t) is the amount of drug expressed
in milligrams, and sk is the time at which the patient takes
the drug.
Pharmacokinetic and pharmacodynamic drug parameters
are usually evaluated in vitro, whereas in vivo parameters
are needed. Pharmacological characteristics of any drug
vary significantly when evaluated in vitro or in vivo. Thus,
the in vivo parameters given by Legrand et al.38 are used
herein. The model used is as follows:
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_T = s dT  bTV (5)
_T = bTV  lT (6)
_V = 1 w
wþw50
 
kT  cV (7)
_w=Kwþ u(t)d(1 sk) (8)
The control strategy is computed taking into account that
i. The effect of antiretroviral drugs has a strong impact on
the value of the parameter k (therefore g1 is assumed to
be zero) as is explained in Mhawej et al.39
ii. A discrete drug trajectory u(t) is derived by means of a
nonlinear control strategy such as feedback lineariza-
tion for impulsive control systems.11
Based on these aforementioned considerations, the
amount of drug really present in the body can be computed.
A full description of the technique is provided by Mhawej
et al.10 and Rivadeneira et al.11
This setup based on impulsive control systems allows var-
iations of the control variable in amounts of drug (milli-
grams) instead of in terms of their efficiency and describes
in a realistic way how the patient follows the therapy.
Some results of this control method are illustrated in
Fig. 2, which represents the infection evolution for different
values of the dosing interval sk. The simulation is performed
when zidovudine (ZDV) is given twice a day (sk = 0.5 days)
following the closed-loop control strategy. In Fig. 2a, the
virus load approaches the desired healthy equilibrium in
the expected time, according to the requirement to reach
200 cells/mm3 within 6 months. In Fig. 2b, a discrete time
scheduling of the antiretroviral drug can be seen.
As we can see, the inclusion of pharmacokinetic and phar-
macodynamic models using in vivo parameters along with
impulsive control becomes a valuable tool to test and de-
sign therapeutical strategies. Note that this result is observed
when considering a ZDV monotherapy. More significant
results could be obtained with multitherapies. Discussions
about the use of multitherapies or the convenience of admin-
istering the drug once, twice, or three times per day; that is, to
consider drug impulses at variable times sk are left open for
future works.
One major advantage of the control schemes cited (like
state feedback) is their ability to minimize the viral load by
means of a time-varying administration strategy aimed at op-
timally adjusting the efficiency of the drugs to the dynamics
of the patient. This means that if the efficiency of the drug is
related to its dosage, no full dosage is needed all the time.
The benefits appear through a reduction of the side effects
caused by the use of dynamically nonoptimal drug doses.
Control of HIV infection with minimum side effects
In Costanza et al.,9 extended dynamics of the HIV infec-
tion model were developed. A new differential equation
was included to model the generation of side effects due
to medication. After that, optimal control theory was imple-
mented to minimize side effects. This subsection resumes
those main results. Side effects appear and evolve during
the therapy process, frequently persisting even if medication
is discontinued. Since the characteristics of these side effects
have a wide range, it is virtually impossible to identify all
disorders provoked by medication in a patient, and some-
times it is difficult to confirm that an eventually arising
disease, different from HIV, is a side effect. However, a com-
parison study on efficacy and side effects for different doses
of ZDV has shown that the incidence of some moderate to
severe side effects was dose related.40,41
Using the percentages of patients affected by these side ef-
fects in the median follow-up period as a reference, an estimate
of the probability that HIV patients present any confirmed side
effect up to a given time after the beginning of medication can
be computed. In the same line of reasoning, these data were
used to describe (approximately) the dynamic behavior of
such a probability p(t) through an equation of the form9.32:
_p = (d0þ d1uþ d2u2þ d3u3)p(1 p)(V þVh)w, p(0) = p0:
(9)
Several considerations based on the structure of Equation
9 need to be taken into consideration at this stage:
FIG. 2. (a) Time evolution of HIV infection during zido-
vudine (ZDV) monotherapy is depicted on the left side. (b)
The doses, administrated twice a day, are computed by
means of a feedback linearizing impulsive control; their am-
plitude is drawn on the right side.
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 The variable u denotes the drug dose, expressed in
grams.
 The variable p, being a probability, should range in
[0,1]. As far as it is recognized that side effects exist
due to medication, it seems consistent that the probabil-
ity must be nondecreasing while drugs consumption
persists. Given the medical consensus recommending
avoiding interruptions in the medication, the condition
u > 0 for significant periods of time seems unavoidable.
 The growth of p as a function of the drug dose u must
be nonlinear. Let us assume, without loss of generality,
that this nonlinearity accepts a power series description.
This is just an approximation that should be improved
with the incoming of new experimental data.
 A small probability of side effects is always present,
which amounts to consider p0s0.
 Side effects are analyzed only in medicated HIV-
infected patients; that is, the viral load is always non-
zero (Vs0). Consequences of the ingestion of drugs,
which are part of highly active antiretroviral therapy,
in HIV-free persons will not be considered. The value
of the parameter g must be fine-tuned with experimen-
tal data.
 The reason for adding a parameter Vh is to avoid the per-
sistence of side effects when the viral load is nearly zero
but the patient is still consuming a high drug dose.
 The parameter d0 should be small but positive because
even when medication is interrupted (u = 0 for some
time), side effects will probably increase due to previ-
ous drug history.
From the numerical data presented by the Nordic Medical
Research Council,40 a set of parameter values have been fit-
ted and tested by simulating new cases and analyzing the re-
sults. The final adopted values can be seen in Costanza et al.9
Empirical approximations for pharmacokinetic and pharma-
codynamic equations were used to relate the real dose with
its efficiency. Since only monotherapies of ZDV were con-
sidered, g2 is assumed to be zero and b = b0 – b1u – b2u2,
where 0 < u < 1.6 g. Costanza et al.9,32 provide further details.
The resulting model is
_T = s dT  (b0 b1u b2u2)TV (10)
_T = (b0 b1u b2u2)TV lT (11)
_V = kT  cV (12)
_p= (d0þ d1uþ d2u2þ d3u3)p(1 p)(V þVh)w (13)
Based on Equations 10–13, a complete scheme of optimi-
zation was carried out to minimize the side effects and max-
imize the immune response, as it is briefly shown hereafter.
These objectives can be represented mathematically by the
following equation:
minu J(u) = min
u
Z T
t0
(a1V(t)þ a2(T(t) T)2þ a4p(t)
þ a3u2(t))dtþ a5(V(t) V)2dt
(14)
where t0 is the initial time, T is the final time of optimization,
and T and V are desired levels of CD4 + T cells and virions,
respectively. The initial conditions were assumed to simu-
late a patient with a recently discovered infection, for in-
stance (0)= 850 CD4/mm3, T*(0)= 41 cells/mm3, V(0) =
3760 copies/mL, p(0) = 0.05.
The main goal9 was to abate the infection, while generat-
ing as few side effects as possible. The optimal control strat-
egy was recovered from the Dynamic Programming solution
to the optimal control problem formulated in Equation 14.9
The corresponding optimal state trajectory was also stored
during the solution process and is depicted in Figs. 3–5. At
each sampling time there also starts a curve, a solution to
the continuous-time flow of Equations 10–13, showing the
expected evolution of the system during the next sampling
period. That curve is truncated at the end of this period,
according to the adopted discretization of the states. The evo-
lution of the ‘‘protocol’’ trajectories (i.e., those correspond-
ing to running the dynamics alone, with u(t)h1.2 and no
optimization whatsoever) has been included in the figures
for comparison.
The optimal solutions succeed in reducing the number of
viral copies below 50 copies/mL in the desired time of 180
days. The virion population decreases strongly at the begin-
ning and the end of the treatment, remaining at intermediate
levels during most of the period, which is not too bad as long
as no deleterious ‘‘peaks’’ occur. At the extreme stages the
optimal drug dose is high, but during most of the treatment
the drug dose values stay around 0.6 g, half of the tested pro-
tocol value. Also, during the application of the control strat-
egy the number of T cells is always higher than 600 CD4/
mm3, which is considered clinically acceptable.42
The value of a4 = 0.08 produced optimal trajectories
whose partial costs (different terms in the total cost of Equa-
tion 14) had an incidence higher than expected on the total
cost. The incidence of these individual costs does not show
a strict monotone behavior with the variation of the weight
a4. However, in general terms it is noted that the growth of
a4 produces a less significant optimal p(t) trajectory (Fig.
5), as expected. A smaller p(t) is associated with a smaller
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u(t), and since a3 was kept fixed, a decrease of the incidence
of drug costs is found for increasing a4, while, as a natural
counterpart, the significance of penalties for departures
from desired state values increases. Keeping the remaining
cost weights fixed, the value of a4 = 0.1 should be taken as
an acceptable upper bound, since its corresponding optimal
control trajectory shows two transient treatment interruptions
(for t 2 f[30, 45] [ [60, 150]g see Ouattara et al.8 for more
details). The latter may not be desired as it may favor the mu-
tation of the virus. This aspect is beyond of the scope of this
review, and is left for further work that can be conducted
considering switching systems for instance.
Conclusions and Research Perspectives
Mathematical models and systems and control solutions,
as provided by feedback and optimal control theory, have
proved to be very useful in the study of several biological
and biochemical systems. Their use allows us to improve
the prediction capabilities of existing HIV models and to
substantiate variable drug dosages that minimize a cost func-
tion, while balancing combined objectives. Such interdisci-
plinary work requires knowledge of the results, tools, and
languages coming from a disjointed scientific community.
The results obtained until now provide a promising outlook
at the outcomes and results that can be expected from a math-
ematical approach of HIV research: improvement of the
knowledge of underlying dynamic processes behind the dis-
ease and development of new pharmacological strategies.
The obtained results show that engineering methods pro-
vide an alternative approach for analyzing the dynamics of
the HIV infection process. For example, engineering meth-
ods provide a successful way to design clinical trials based
not only on medical knowledge but also on quantitative anal-
ysis, allowing for a reduction in the number of blood samples
required from each patient, and minimizing monetary cost.
Based on the presented models, mathematical analyses,
and control methods, physicians have more tools at their dis-
posal to help the decision-making process at different stages
of the infection. The estimation of some parameters appear-
ing in the presented mathematical models can be used in the
diagnosis as was shown in the section Prospective Research:
Infection Control and Drug Dosage. The pharmacodynamic
and pharmacokinetic parameters that have been used in
this review may be replaced by adequate parameters corre-
sponding to more recent drug therapies whenever available.
It is worth mentioning that the values of such parameters as
the free virus decay rate,43 the death rate of actively infected
cells,44 and the turnover rate of target cells45,46 are still con-
troversial. A multidrug treatment yields also a more sophis-
ticated model.47 The methods reviewed here can be adapted
and used without major modification by changing the values
of some parameters; their general conclusions remain valid.
Post diagnosis, the control schemes presented in this re-
view article are useful to design optimal treatment strategies
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customized for each patient. The design of multi-objective
costs can generate optimal doses according to the immuno-
logical and virological state of the patient as well as mitigat-
ing side effects and costs.
Research perspectives include a long-term drug optimiza-
tion that takes into account the risk of treatment-resistant mu-
tations, within the framework of so-called switching systems,
since the characteristics of the virus dynamics depend on the
virus strain, which can abruptly change once mutations
occur. This investigation is mandatory for a real-life applica-
tion and is the topic of future research.
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